Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPF9ZM)

• Drug Name: Obatoclax Drug Info
• Synonyms: CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 11404337
  CAS Number: CAS 803712-67-6
  TTD Drug ID: DMPF9ZM

Molecule-Related Drug Atlas

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[2]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[2]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[3]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[4]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[5]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[6]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[7]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-21	DM18UA5	N. A.	N. A.	Patented	[7]

Drug(s) Targeting Apoptosis regulator Bcl-2 (BCL-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MCI-186	DM8ZHP1	Amyotrophic lateral sclerosis	8B60.0	Approved	[8]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[9]
GDC-0199	DMH0QKA	Chronic lymphocytic leukaemia	2A82.0	Approved	[10]
ABT-263	DMNE56X	Myelofibrosis	2A20.2	Phase 3	[11]
Taxol/Paraplatin/Herceptin	DML6GAN	Breast cancer	2C60-2C65	Phase 3	[12]
Oblimersen	DM7KI4E	Melanoma	2C30	Phase 3	[13]
RG7601	DMDVAFP	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[10]
Thymoquinone	DMVDTR2	Polycystic ovarian syndrome	5A80.1	Phase 2/3	[14]
PI-88/Taxotere	DM4FIWC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
Gossypol	DMJWE3I	Prostate cancer	2C82.0	Phase 2	[16]

Drug(s) Targeting Apoptosis regulator Bcl-xL (BCL-xL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-263	DMNE56X	Myelofibrosis	2A20.2	Phase 3	[11]
APG-1252	DM8O3R9	Small-cell lung cancer	2C25.Y	Phase 1/2	[17]
AZD0466	DMWLZI6	Hematologic tumour	2B33.Y	Phase 1/2	[18]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[7]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-21	DM18UA5	N. A.	N. A.	Patented	[7]
Indole-based analog 3	DMTEYQJ	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-26	DM8GOH3	N. A.	N. A.	Patented	[7]
PMID27744724-Compound-27	DMV6MLC	N. A.	N. A.	Patented	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Inhibitor	[1]
Apoptosis regulator Bcl-xL (BCL-xL)	TTU1E82	B2CL1_HUMAN	Inhibitor	[1]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[1]

References

• [1] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [4] Clinical pipeline report, company report or official report of AbbVie.
• [5] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [6] Clinical pipeline report, company report or official report of Amgen.
• [7] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [8] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [9] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [10] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
• [11] Clinical pipeline report, company report or official report of Roche (2009).
• [12] Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
• [13] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [14] Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
• [15] Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
• [16] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
• [17] Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
• [18] Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.